🎉 M&A multiples are live!
Check it out!

Cassava Sciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Cassava Sciences and similar public comparables like Pharming, Vivoryon Therapeutics, and Julphar.

Cassava Sciences Overview

About Cassava Sciences

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer’s disease dementia.


Founded

1998

HQ

United States of America
Employees

30

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$13.6M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Cassava Sciences Financials

Cassava Sciences has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Cassava Sciences achieved revenue of n/a and an EBITDA of -$141M.

Cassava Sciences expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Cassava Sciences valuation multiples based on analyst estimates

Cassava Sciences P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$104M -$141M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$76.2M -$97.2M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Cassava Sciences Stock Performance

As of March 14, 2025, Cassava Sciences's stock price is $3.

Cassava Sciences has current market cap of $135M, and EV of $13.6M.

See Cassava Sciences trading valuation data

Cassava Sciences Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$13.6M $135M XXX XXX XXX XXX $-1.27

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Cassava Sciences Valuation Multiples

As of March 14, 2025, Cassava Sciences has market cap of $135M and EV of $13.6M.

Cassava Sciences's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Cassava Sciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Cassava Sciences and 10K+ public comps

Cassava Sciences Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $13.6M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -0.1x XXX XXX XXX
P/E -5.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Cassava Sciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Cassava Sciences Valuation Multiples

Cassava Sciences's NTM/LTM revenue growth is n/a

Cassava Sciences's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $4.7M for the same period.

Over next 12 months, Cassava Sciences's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Cassava Sciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Cassava Sciences and other 10K+ public comps

Cassava Sciences Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 35% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $4.7M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Cassava Sciences Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Biopharmaceuticals comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Cassava Sciences M&A and Investment Activity

Cassava Sciences acquired  XXX companies to date.

Last acquisition by Cassava Sciences was  XXXXXXXX, XXXXX XXXXX XXXXXX . Cassava Sciences acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Cassava Sciences

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Cassava Sciences

When was Cassava Sciences founded? Cassava Sciences was founded in 1998.
Where is Cassava Sciences headquartered? Cassava Sciences is headquartered in United States of America.
How many employees does Cassava Sciences have? As of today, Cassava Sciences has 30 employees.
Who is the CEO of Cassava Sciences? Cassava Sciences's CEO is Mr. Richard J. Barry.
Is Cassava Sciences publicy listed? Yes, Cassava Sciences is a public company listed on NAS.
What is the stock symbol of Cassava Sciences? Cassava Sciences trades under SAVA ticker.
When did Cassava Sciences go public? Cassava Sciences went public in 2000.
Who are competitors of Cassava Sciences? Similar companies to Cassava Sciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Cassava Sciences? Cassava Sciences's current market cap is $135M
Is Cassava Sciences profitable? Yes, Cassava Sciences is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.